ABD Gıda ve İlaç Dairesi (FDA), Pfizer ile BioNTech’in geliştirdiği corona virüsü aşısının üçüncü dozuna yeşil ışık yakmasına BioNTech’in CEO’su Uğur Şahin’den yanıt geldi
Sözcü: “Bugün klinik verilerin de desteğiyle birlikte üçüncü doz aşının endişe yaratan varyantlara karşı güçlü bir bağışıklık yarattığının altı çizildi ve bununla birlikte acil kullanım onayı verildi ve bu durum kamu sağlığının ihtiyacını karşılayabilecektir. SARS-CoV-2 virüsünü izlemeyi sürdüreceğiz ve potansiyel olarak çıkabilecek varyantlara karşı hazırlıklı olacağız” dedi.
LinkedIn: When we started Project Lightspeed the grand mission was to make a #vaccine for the world. Today, we announced at the #G20 Summit, together with our partner Pfizer, that we’ll deliver 2 billion doses of our #COVID19 vaccine to low- and middle-income countries over the next 1.5 years. The first 1 billion doses will be provided this year.
This is one milestone in a string of many:
– As of yesterday, we’ve delivered ~540 million doses to >90 countries
– In parallel, we’ve increased our capacity for 2021 to up to 3 billion doses
– We reached agreements to deliver additional doses with many countries, incl. the EU, and most recently Turkey, which will receive 120 million #BNT162b2 doses
– We’re continuing to conduct clinical trials to make our COVID-19 vaccine available to all who could potentially benefit. We’ve submitted data on BNT162b2’s tolerability and efficacy in 12- to 15-year-old adolescents; the #FDA has granted approval and we’e awaiting feedback from the European Medicines Agency
What motivates us is the steady decline in new COVID-19 cases as vaccination campaigns progress in many countries. Bringing the pandemic to an end is an immense challenge that we can only overcome together. We’ll continue to work every day to contribute our part to achieving this goal.
